Johnson & Johnson Reports Positive Two-year Data From ICONIC-LEAD Study With ICOTYDE

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

Johnson & Johnson (JNJ) reported positive two-year Phase 3 trial results for ICOTYDE, an oral peptide for plaque psoriasis, with 72% of patients achieving significant skin improvement. The company offers a 1.98% dividend yield, a 55% payout ratio, and a 4.9% 3-year dividend growth rate, but its stock is 32% overvalued relative to its GF Value. JNJ has a GF Score of 83/100, indicating strong financial health and profitability, though insider activity shows significant net selling.

Johnson & Johnson (JNJ) presented two-year data from its Phase 3 ICONIC-LEAD study of Icotyde for psoriasis, showing sustained skin clearance and safety. The drug is approved in the U.S., Europe, Japan, and China. JNJ shares rose 15% premarket. Icotyde is also being studied for other conditions.

Johnson & Johnson (JNJ) reported two-year Phase 3 data for ICOTYDE in treating plaque psoriasis, showing 72% of patients achieved 90% skin improvement and 70% had clear/almost clear skin. Retreatment data showed 85% response recovery. No new safety issues were found. ICOTYDE is approved in major markets. Additional studies are ongoing for psoriasis, psoriatic arthritis, and inflammatory bowel diseases.

Johnson & Johnson (JNJ) presented two-year Phase 3 data for ICOTYDE® (icotrokinra) at Fall Clinical Dermatology 2026. The study showed high, sustained response rates in adults and adolescents with plaque psoriasis, with 72% achieving clear or almost clear skin and a favorable safety profile. ICOTYDE is the first targeted oral peptide blocking the IL-23 receptor. The company highlights its potential as a first-line systemic therapy.

Johnson & Johnson (JNJ) reported Q2 sales of $25.3B, up 6.6%, and raised its 2026 outlook. Adjusted EPS grew 4.7% to $2.90, with full-year guidance increased to $11.60-$11.75. JNJ expects $100.8B-$101.4B in annual revenue. Analysts debate its valuation, with JPMorgan remaining Neutral and UBS recommending Buy. AbbVie (ABBV) is compared for valuation context.